 |
|
|
| |
Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE1 and PROVE2 Trials
|
| |
| |
Reported by Jules Levin
AASLD Oct 31-Nov 3 2009, Boston, MA
Gregory T. Everson1, Geoffrey M. Dusheiko2, Peter Ferenci3, Katia Alves4, Leif Bengtsson4, Lindsay McNair4, John G. McHutchison5, Andrew Muir5, Jean-Michel Pawlotsky6, Stefan Zeuzem7
1University of Colorado Denver, Denver, CO, USA; 2Royal Free and University College School of Medicine, London, United Kingdom; 3University of Vienna, Vienna, Austria; 4Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 5Duke University Medical Center, Durham, NC, USA; 6Hopital Henri Mondor, Creteil, France; 7Johann Wolfgang Goethe University Medical Center, Frankfurt/Main, Germany.
Address correspondence to: Gregory T. Everson, University of Colorado School of Medicine, Denver, CO 80262,
REFERENCES
1. Lin K, et al. Antimicrob Agents Chemother 2004;40:4784-92.
2. Perni RB, et al. Antimicrob Agents Chemother 2006;50:899-909.
3. McHutchison JG, et al. N Engl J Med 2009;360:1827-1838.
4. Hezode C, et al. N Engl J Med 2009;360:1839-1850.
5. Fried MW, et al. N Engl J Med 2002;347:975-982.
6. Manns MP, et al. Lancet 2001;358:958-965.
7. Hadziyannis SJ, et al. Ann Intern Med 2004;140:346-355.
8. Conjeevaram HS, et al. Gastroenterology 2006;131:470-477.
9. Patton HM, et al. J Hepatol 2004;40:484-490.
10. Dev A, et al. Clin Liver Dis 2004;8:881-892.
11. Conjeevaram HS, et al. Hepatology 2007;45:80-87.
|
| |
|
|
|
|
|
